cancer - search results

Lorna Rothery spoke to the Cancer Drug Development Forum’s Managing Director, Professor Jaap Verweij and Chairperson of the CDDF Board of Directors, Professor Ruth Plummer, about opportunities and challenges in oncology research and treatment.

Jaap Verweij, M.D., Ph.D is an Emeritus Professor of Medical Oncology, and former Dean of the Faculty of Medicine at Erasmus University Medical Centre He served as chair of the Department of Medical Oncology, and chair of the Daniel den Hoed Cancer Center at the Erasmus University Medical Centre from...

Ruth Plummer is a Professor of Experimental Cancer Medicine in the Translational and Clinical Research Institute, Newcastle University, and an honorary consultant medical oncologist in Newcastle Hospitals NHS Foundation Trust. Prof. Plummer is director of the Sir Bobby Robson Cancer Trials Research Centre within the Northern Centre for Cancer Care....

Is the a link between liver inflammation and cancer treatment outcomes? Researchers have found why certain cancers become resistant to immunotherapy.

A scarcity of suitable therapies and geographic disparities in access to care are impacting survival rates for children with cancer; Lorna Rothery spoke to the European branch of Childhood Cancer International, a pan-European organisation committed to improving outcomes for children and adolescents affected by cancer.

Researchers suggest that microwave ablation, a minimally invasive procedure, could offer comparable progression-free survival rates to surgery with fewer complications.

Daniel J. Murphy, Professor of Lung Cancer & Mesothelioma at the University of Glasgow, School of Cancer Sciences, discusses opportunities for improving cancer research and care through the use of genetically engineered mouse models.

Nanotextures on nanoparticles and implants to kill cancer cells in a more targeted manner may just be the key to tackling resistance to traditional cancer drugs.

A minimally invasive treatment for prostate cancer, using a combination of MRI and transurethral ultrasound, has shown effectiveness in a recent study.

Mark Lawler, from the Patrick G Johnston Centre for Cancer Research at Queen’s University Belfast, reflects on key milestones in cancer policy initiatives and how data support innovative cancer research, optimal care and equity of access.

Dr Alice Di Pasquale, Scientific Research Officer at Breast Cancer UK, explains why more must be done to increase awareness of Endocrine Disrupting Chemicals and breast cancer risk.

Peter J. Houghton from Greehey Children’s Cancer Research Institute and Mary-Ann Bjornsti from the University of Alabama discuss some of the key challenges in the development of therapies for pediatric cancer care.

New research looks at cancer cases in the UK, revealing complex factors driving progress and challenges.

A new drug development could help those battling pancreatic cancer, one of the most challenging cancers to treat.

Satyajit Hari Kulkarni and Christopher H. Contag from the Institute for Quantitative Health Science and Engineering focus on engineered endosymbionts, which they argue is a paradigm shift in anticancer bacteriotherapy toward killing tumors from the inside out.

Researchers have identified 140 genes that could change how non-small cell lung cancer (NSCLC) patients are treated with immunotherapy and low-dose radiation.

Paul Landau, CEO of Careology, a digital cancer care platform used by the NHS and private health sector, posits the need for smart investment into digital tools to support cancer care and maximise the efficiency of resources.

A new cutting-edge artificial intelligence tool has been developed to revolutionise cancer treatment.

The past ten years have seen significant progress in cancer care, detecting cancers earlier and managing them more successfully and less invasively on a global scale.